Modern pharmacotherapy of atherosclerosis-associated peripheral arterial diseases
AbstractAbout 6% of adults worldwide have atherosclerosis and thrombosis of the lower limb arteries-peripheral artery disease (PAD), and the prevalence of this disease is increasing. PAD causes legs of pain when walking (intermittent claudication), or even at rest, reduces the quality of life associated with health, can lead to tissue loss and a high risk of complications, including myocardial infarction, stroke, amputation and death. This review describes the current possibilities and directions of drug treatment of PAD. The described methods of treating PAD include antithrombotic drugs such as aspirin and clopidogrel, as well as drugs for the treatment of dyslipidemia, hypertension. Randomized controlled trials have shown that these treatments reduce the risk of serious adverse events. The cilostazol and other medications, physical therapy, as well as revascularization are modern options for the treatment of symptoms and complications of PAD, but only a comprehensive understanding of the possibilities of non-surgical treatment allows the practitioner to avoid both premature surgery and not to miss the time for revascularization of the lower limbs arteries.
Keywords:pharmacotherapy of peripheral arterial diseases (PAD); statins in PAD; antiplatelet agents in PAD; anticoagulants in PAD; peripheral vasodilators in PAD; smoking cessation in treatment of PAD
Funding. The study had no sponsor support.
Conflict of interest. The authors declare no conflict of interest.
Authors’ contribution. writing the article – Agarkov M.V.; article review, technical support, translation – Lazakovich D.N.; assistance in collecting data from the head of the endovascular care service – Gertsog O.B.; assistance in collecting data from the head of the surgical service; organization of patient routing, general management – Lubiviy E.D.; educational and methodological management, article editing – Kozlov K.L.; writing the article, article editing – Obrezan A.G.
For citation: Agarkov M.V., Lazakovich D.N., Kozlov K.L., Gertsog O.B., Lubiviy E.D., Obrezan A.G. Modern pharmacotherapy of atherosclerosis-associated peripheral arterial diseases. Kardiologiya: novosti, mneniya, obuchenie [Cardiology: News, Opinions, Training]. 2023; 11 (2): 52–60. DOI: https://doi.org/10.33029/2309-1908-2023-11-2-52-60 (in Russian)
References
1. Shu J., Santulli G. Update on peripheral artery disease: Epidemiology and evidence-based facts. Atherosclerosis. 2018; 275: 379–81. DOI: https://www.doi.org/10.1016/j.atherosclerosis.2018.05.033. Epub 2018 May 22. PMID: 29843915; PMCID: PMC 6113064.
2. Ohman E.M., Bhatt D.L., Steg P.G., Goto S., Hirsch A.T., Liau C.S., Mas J.L., Richard A.J., Röther J., Wilson P.W.; REACH registry investigators. The Reduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006; 151: 786. e1–786.10. DOI: https://www.doi.org/10.1016/j.ahj.2005.11.004
3. Fowkes F.G.R., Murray G.D., Butcher I., Heald C.L., Lee R.J., Chambless L.E., Folsom A.R., Hirsch A.T., Dramaix M., deBacker G., et al; Ankle Brachial Index Collaboration. Ankle brachial index combined with framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008; 300: 197–208. DOI: https://www.doi.org/10.1001/jama.300.2.197
4. Cotter G., Cannon C.P., McCabe C.H., Michowitz Y., Kaluski E., Charlesworth A., Milo O., Bentley J., Blatt A., Krakover R., et al; OPUS-TIMI 16 Investigators. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the orbofiban in patients with unstable coronary syndromes-thrombolysis in myocardial infarction (OPUS-TIMI) 16 study. Am Heart J. 2003; 145: 622–7. DOI: https://www.doi.org/10.1067/mhj.2003.6
5. Norgren L., Hiatt W.R., Dormandy J.A., Nehler M.R., Harris K.A., Fowkes F.G.; TASC II Working Group. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007; 45 (Suppl S): S 5-67. DOI: https://www.doi.org/10.1016/j.jvs.2006.12.037. PMID: 17223489.
6. Valji K. The 2020 Charles T. Dotter lecture: “Why are we doing this procedure?”: Asking the fundamental question in interventional radiology. J Vasc Interv Radiol. 2021; 32 (7): 936–40. DOI: https://www.doi.org/10.1016/j.jvir.2021.04.002. PMID: 34210481
7. Sharrett A.R., Ballantyne C.M., Coady S.A., Heiss G., Sorlie P.D., Catellier D., Patsch W.; Atherosclerosis Risk in Communities Study Group. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2001; 104: 1108–13. DOI: https://www.doi.org/10.1161/hc3501.095214
8. Grundy S.M., Stone N.J., Bailey A.L., Beam C., Birtcher K.K., Blumenthal R.S., Braun L.T., de Ferranti S., Faiella-Tommasino J., Forman D.E., et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol. 2019; 73: e285– e350. DOI: https://www.doi.org/10.1016/j.jacc.2018.11.003
9. Gerhard-Herman M.D., Gornik H.L., Barrett C., Barshes N.R., Corriere M.A., Drachman D.E., Fleisher L.A., Fowkes F.G., Hamburg N.M., Kinlay S., et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation. 2017; 135: e686–e725. DOI: https://www.doi.org/10.1161/CIR.0000000000000470
10. Pischon T., Girman C.J., Sacks F.M., Rifai N., Stampfer M.J., Rimm E.B. Non- high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation. 2005; 112: 3375–83. DOI: https://www.doi.org/10.1161/CIRCULATIONAHA.104.532499
11. Catapano A.L., Graham I., De Backer G., Wiklund O., Chapman M.J., Drexel H., Hoes A.W., Jennings C.S., Landmesser U., Pedersen T.R., et al; Additional Contributor. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Rev Esp Cardiol (Engl Ed). 2017; 70: 115. DOI: https://www.doi.org/10.1016/j.rec.2017.01.002
12. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360: 7–22. DOI: https://www.doi.org/10.1016/S0140-6736(02)09327-3
13. Murphy S.A., Cannon C.P., Blazing M.A., Giugliano R.P., White J.A., Lokhnygina Y., Reist C., Im K., Bohula E.A., Isaza D., et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016; 67: 353–61. DOI: https://www.doi.org/10.1016/j.jacc.2015.10.077
14. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344 (8934): 1383–9. PMID: 7968073.
15. Heart Protection Study Collaborative Group. Randomized trial of the effects of cholesterol-lowering with simvastatin on peripheral vascular and other major vascular outcomes in 20,536 people with peripheral arterial disease and other high-risk conditions. J Vasc Surg. 2007; 45: 645–54; discussion 653–4. DOI: https://www.doi.org/10.1016/j.jvs.2006.12.054
16. Sohn M.W., Meadows J.L., Oh E.H., Budiman-Mak E., Lee T.A., Stone N.J., Pearce W.B. Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg. 2013; 58: 1578-1585.e1. DOI: https://www.doi.org/10.1016/j.jvs.2013.06.069
17. Hsu C.Y., Chen Y.T., Su Y.W., Chang C.C., Huang P.H., Lin S.J. Statin therapy reduces future risk of lower-limb amputation in patients with diabetes and peripheral artery disease. J Clin Endocrinol Metab. 2017; 102: 2373-81. DOI: https://www.doi.org/10.1210/jc.2016-3717
18. Ohman E.M., Bhatt D.L., Steg P.G., Goto S., Hirsch A.T., Liau C.S., Mas J.L., Richard A.J., Röther J., Wilson P.W.; REACH Registry Investigators. The Reduction of Atherothrombosis for Continued Health (REACH) registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J. 2006; 151: 786. e1-786.10. DOI: https://www.doi.org/10.1016/j.ahj.2005.11.004
19. Sofat S., Chen X., Chowdhury M.M., Coughlin P.A. Effects of statin therapy and dose on cardiovascular and limb outcomes in peripheral arterial disease: a systematic review and meta-analysis. Eur J Vasc Endovasc Surg. 2021; 62 (3): 450-61. DOI: https://www.doi.org/10.1016/j.ejvs.2021.05.025. Epub 2021 Aug 10. PMID: 34389230.
20. CAPRIE Steering Committee. A randomised, blinded, trial of Clopidogrel Versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE). CAPRIE steering committee. Lancet. 1996; 348: 1329-39. DOI: https://www.doi.org/10.1016/s0140-6736(96)09457-3
21. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H. et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-57. DOI: https://www.doi.org/10.1056/NEJMoa0904327
22. Hsia J., Kavanagh S.T., Hopley C.W., Baumgartner I., Berger J.S., Fowkes G.R., Jones W.S., Mahaffey K.W., Norgren L., Patel M.R., Rockhold F., Blomster J., Katona B.G., Hiatt W.R., Bonaca M.P. Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y 12 inhibitors: Insights from the EUCLID trial. Vasc Med. 2021; 26 (6): 608-12. DOI: https://www.doi.org/10.1177/1358863X211017641. Epub 2021 Jun 3. PMID: 34082620.
23. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., Horrow J., Husted S., James S., Katus H., Mahaffey K.W., Scirica B.M., Skene A., Steg P.G., Storey R.F., Harrington R.A.; PLATO Investigators; Freij A., Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361 (11): 1045-57. DOI: https://www.doi.org/10.1056/NEJMoa0904327. Epub 2009 Aug 30. PMID: 19717846.
24. Scheen A.J. L’étude clinique du mois. L’étude CHARISMA: à la recherche de la meilleure stratégie antiagrégante plaquettaire en prévention cardio-vasculaire [The CHARISMA study: in search of the best antiplatelet strategy for cardiovascular prevention]. Rev Med Liege. 2006; 61 (9): 656-61. French. PMID: 17112168.
25. Bonaca M.P., Goto S., Bhatt D.L., Steg P.G., Storey R.F., Cohen M., Goodrich E., Mauri L., Ophuis T.O., Ruda M., Špinar J., Seung K.B., Hu D., Dalby A.J., Jensen E., Held P., Morrow D.A., Braunwald E., Sabatine M.S. Prevention of stroke with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54 (prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirin-thrombolysis in myocardial infarction 54). Circulation. 2016; 134 (12): 861-71.
26. 2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with ESVS. European Heart Journal. 2017. DOI: https://www.doi.org/10.1093/eurheartj/ehx095
27. Narula N., Dannenberg A.J., Olin J.W., Bhatt D.L., Johnson K.W., Nadkarni G., Min J., Torii S., Poojary P., Anand S.S., Bax J.J., Yusuf S., Virmani R., Narula J. Pathology of peripheral artery disease in patients with critical limb ischemia. J Am Coll Cardiol. 2018; 72 (18): 2152-63. DOI: https://www.doi.org/10.1016/j.jacc.2018.08.002. Epub 2018 Aug 27. PMID: 30166084.
28. Hurlen M., Abdelnoor M., Smith P., Erikssen J., Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002; 347: 969-74. DOI: https://www.doi.org/10.1056/NEJMoa020496
29. Anand S.S., Yusuf S., Pogue J., Weitz J.I., Flather M. Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: Organization to Assess Strategies for Ischemic Syndromes (OASIS) pilot study results. Circulation. 1998; 98: 1064-70. DOI: https://www.doi.org/10.1161/01.cir.98.11.1064
30. Anand S., Yusuf S., Xie C., Pogue J., Eikelboom J., Budaj A., Sussex B., Liu L., Guzman R., Cina C.; Warfarin antiplatelet vascular evaluation trial investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med. 2007; 357: 217-27. DOI: https://www.doi.org/10.1056/NEJMoa065959
31. Bauersachs R.M., Szarek M., Brodmann M., Gudz I., Debus E.S., Nehler M.R., Anand S.S., Patel M.R., Hess C.N., Capell W.H., Rogers K., Muehlhofer E., Haskell L.P., Berkowitz S.D., Hiatt W.R., Bonaca M.P.; VOYAGER PAD Committees and Investigators. Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. J Am Coll Cardiol. 2021; 78 (4): 317-26. DOI: https://www.doi.org/10.1016/j.jacc.2021.05.003. Epub 2021 May 16. PMID: 34010631.
32. Bosch J., et al. Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. Can J Cardiol. 2017; 33: 1027-35.
33. Farkas K., Kolossváry E., Járai Z. Simple assessment of quality of life and lower limb functional capacity during cilostazol treatment - results of the SHort-tERm cIlostazol eFFicacy and quality of life (SHERIFF) study. Vasa. 2020; 49 (3): 235-42. DOI: https://www.doi.org/10.1024/0301-1526/a000845. Epub 2020 Jan 27. PMID: 31983287.
34. Sleight P. The HOPE Study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000; 1 (1): 18-20. DOI: https://www.doi.org/10.3317/jraas.2000.002. PMID: 11967789.
35. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G.; Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-53. DOI: https://www.doi.org/10.1056/NEJM200001203420301
36. Aboyans V., Ricco J.B., Bartelink M.E.L., Björck M., Brodmann M., Cohnert T., Collet J.P., Czerny M., De Carlo M., Debus S., et al; ESC Scientific Document Group. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. Endorsed by: the European Stroke Organization (ESO) the task force for the diagnosis and treatment of peripheral arterial dis- eases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018; 39: 763-816. DOI: https://www.doi.org/10.1093/eurheartj/ehx095
37. Willigendael E.M., Teijink J.A., Bartelink M.L., Kuiken B.W., Boiten J., Moll F.L., Büller H.R., Prins M.H. Influence of smoking on incidence and prevalence of peripheral arterial disease. J Vasc Surg. 2004; 40: 1158-65. DOI: https://www.doi.org/10.1016/j.jvs.2004.08.049
38. Ding N., Sang Y., Chen J., Ballew S.H., Kalbaugh C.A., Salameh M.J., Blaha M.J., Allison M., Heiss G., Selvin E., et al. Cigarette smoking, smoking cessation, and long-term risk of 3 major atherosclerotic diseases. J Am Coll Cardiol. 2019; 74: 498-507. DOI: https://www.doi.org/10.1016/j.jacc.2019.05.049
39. Armstrong E.J., Wu J., Singh G.D., Dawson D.L., Pevec W.C., Amsterdam E.A., Laird J.R. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg 2014; 60: 1565-71. DOI: https://www.doi.org/10.1016/j.jvs.2014.08.064
40. Hennrikus D., Joseph A.M., Lando H.A., Duval S., Ukestad L., Kodl M., Hirsch A.T. Effectiveness of a smoking cessation program for peripheral artery disease patients: a randomized controlled trial. J Am Coll Cardiol. 2010; 56: 2105- 12. DOI: https://www.doi.org/10.1016/j.jacc.2010.07.031
41. Patnode C.D., Henderson J.T., Thompson J.H., Senger C.A., Fortmann S.P., Whitlock E.P. Behavioral counseling and pharmacotherapy interventions for tobacco cessation in adults, including pregnant women: a review of reviews for the U.S. preventive services task force. Ann Intern Med. 2015; 163: 608-21. DOI: https://www.doi.org/10.7326/M15-0171
42. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003; 9 (6): 669-76. DOI: https://www.doi.org/10.1038/nm0603-669. PMID: 12778165.
43. Saaristo A., Veikkola T., Tammela T., Enholm B., Karkkainen M.J., Pajusola K., Bueler H., Ylä-Herttuala S., Alitalo K. Lymphangiogenic gene therapy with minimal blood vascular side effects. J Exp Med. 2002; 196 (6): 719-30. DOI: https://www.doi.org/10.1084/jem.20020587. PMID: 12235206; PMCID: PMC 2194057.
44. Isner J.M., Pieczek A., Schainfeld R., Blair R., Haley L., Asahara T., Rosenfield K., Razvi S., Walsh K., Symes J.F. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet. 1996; 348 (9024): 370-4. DOI: https://www.doi.org/10.1016/s0140-6736(96)03361-2. PMID: 8709735.
45. Mäkinen K., Manninen H., Hedman M., Matsi P., Mussalo H., Alhava E., Ylä-Herttuala S. Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther. 2002; 6 (1): 127-33. DOI: https://www.doi.org/10.1006/mthe.2002.0638. PMID: 12095313.
46. Kusumanto Y.H., van Weel V., Mulder N.H., Smit A.J., van den Dungen J.J., Hooymans J.M., Sluiter W.J., Tio R.A., Quax P.H., Gans R.O., Dullaart R.P., Hospers G.A. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther. 2006; 17 (6): 683-91. DOI: https://www.doi.org/10.1089/hum.2006.17.683. PMID: 16776576.
47. Muona K., Mäkinen K., Hedman M., Manninen H., Ylä-Herttuala S. 10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb. Gene Ther. 2012; 19 (4): 392-5. DOI: https://www.doi.org/10.1038/gt.2011.109. Epub 2011 Jul 21. PMID: 21776026.
48. Comerota A.J., Throm R.C., Miller K.A., Henry T., Chronos N., Laird J., Sequeira R., Kent C.K., Bacchetta M., Goldman C., Salenius J.P., Schmieder F.A., Pilsudski R. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002; 35 (5): 930-6. DOI: https://www.doi.org/10.1067/mva.2002.123677. PMID: 12021709.
49. Nikol S., Baumgartner I., Van Belle E., Diehm C., Visoná A., Capogrossi M.C., Ferreira-Maldent N., Gallino A., Graham Wyatt M., Dinesh Wijesinghe L., Fusari M., Stephan D., Emmerich J., Pompilio G., Vermassen F., Pham E., Grek V., Coleman M., Meyer F. Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia. Mol Ther. 2008; 16 (5): 972-8. DOI: https://www.doi.org/10.1038/mt.2008.33. Epub 2016 Dec 8. PMID: 28178491.
50. Belch J., Hiatt W.R., Baumgartner I., Driver I.V., Nikol S., Norgren L., Van Belle E.; TAMARIS Committees and Investigators. Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet. 2011; 377 (9781): 1929-37. DOI: https://www.doi.org/10.1016/S0140-6736(11)60394-2. Epub 2011 May 28. PMID: 21621834.
51. Nakamura T., Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci. 2010; 86 (6): 588-610. DOI: https://www.doi.org/10.2183/pjab.86.588. PMID: 20551596; PMCID: PMC 3081175.
52. Kaga T., Kawano H., Sakaguchi M., Nakazawa T., Taniyama Y., Morishita R. Hepatocyte growth factor stimulated angiogenesis without inflammation: differential actions between hepatocyte growth factor, vascular endothelial growth factor and basic fibroblast growth factor. Vascul Pharmacol. 2012; 57 (1): 3-9. DOI: https://www.doi.org/10.1016/j.vph.2012.02.002. Epub 2012 Feb 14. PMID: 22361334.
53. Hayashi S., Morishita R., Nakamura S., Yamamoto K., Moriguchi A., Nagano T., Taiji M., Noguchi H., Matsumoto K., Nakamura T., Higaki J., Ogihara T. Potential role of hepatocyte growth factor, a novel angiogenic growth factor, in peripheral arterial disease: downregulation of HGF in response to hypoxia in vascular cells. Circulation. 1999; 100 (19, Suppl): II301-8. DOI: https://www.doi.org/10.1161/01.cir.100.suppl_2.ii-301. PMID: 10567320.
54. Taniyama Y., Morishita R., Hiraoka K., Aoki M., Nakagami H., Yamasaki K., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation. 2001; 104 (19): 2344-50. DOI: https://www.doi.org/10.1161/hc4401.098470. PMID: 11696476.
55. Taniyama Y., Morishita R., Aoki M., Nakagami H., Yamamoto K., Yamazaki K., Matsumoto K., Nakamura T., Kaneda Y., Ogihara T. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: preclinical study for treatment of peripheral arterial disease. Gene Ther. 2001; 8 (3): 181-9. DOI: https://www.doi.org/10.1038/sj.gt.3301379. PMID: 11313789.
56. Hiraoka K., Koike H., Yamamoto S., Tomita N., Yokoyama C., Tanabe T., Aikou T., Ogihara T., Kaneda Y., Morishita R. Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA. Circulation. 2003; 108 (21): 2689-96. DOI: https://www.doi.org/10.1161/01.CIR.0000093275.78676.F4. Epub 2003 Oct 20. PMID: 14568901.
57. Koike H., Morishita R., Iguchi S., Aoki M., Matsumoto K., Nakamura T., Yokoyama C., Tanabe T., Ogihara T., Kaneda Y. Enhanced angiogenesis and improvement of neuropathy by cotransfection of human hepatocyte growth factor and prostacyclin synthase gene. FASEB J. 2003; 17 (6): 779-81. DOI: https://www.doi.org/10.1096/fj.02-0754fje. Epub 2003 Feb 5. PMID: 12586736.
58. Morishita R., Makino H., Aoki M., Hashiya N., Yamasaki K., Azuma J., Taniyama Y., Sawa Y., Kaneda Y., Ogihara T. Phase I/IIa clinical trial of therapeutic angiogenesis using hepatocyte growth factor gene transfer to treat critical limb ischemia. Arterioscler Thromb Vasc Biol. 2011; 31 (3): 713-20. DOI: https://www.doi.org/10.1161/ATVBAHA.110.219550. Epub 2010 Dec 23. PMID: 21183732.
59. Shigematsu H., Yasuda K., Iwai T., Sasajima T., Ishimaru S., Ohashi Y., Yamaguchi T., Ogihara T., Morishita R. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia. Gene Ther. 2010; 17 (9): 1152-61. DOI: https://www.doi.org/10.1038/gt.2010.51. Epub 2010 Apr 15. PMID: 20393508.
60. Suchkov I.A., Kalinin R.E., Mzhavanadze N.D., Kamaev A.A., Burenin A.G., Larkov R.N. Efficacy and safety of a drug based on regulatory polypeptides of vessels for treatment of intermittent claudication (results of a multicenter, double-blind, placebo-controlled randomized trial). Angiology and Vascular Surgery. 2023; 29 (1): 23-33. DOI: https://doi.org/10.33029/1027-6661-2023-29-1-23-33 (in Russian [Сучков И.А., Калинин Р.Е., Мжаванадзе Н.Д. и др. Эффективность и безопасность применения препарата на основе регуляторных полипептидов сосудов для лечения перемежающейся хромоты (результаты многоцентрового двойного слепого плацебо-контролируемого рандомизированного исследования) // Ангиология и сосудистая хирургия. 2023. Т. 29, № 1. С. 23-33. DOI: https://www.doi.org/10.33029/1027-6661-2023-29-1-23-33. EDN RKWFDD.]